| Line 29: |
Line 29: |
| | ==Liver Function== | | ==Liver Function== |
| | | | |
| − | * PROTEIN METABOLISM
| + | ===Protein Synthesis=== |
| | Protein synthesis, regulation of amino acids Ammonia synthesis and detoxification | | Protein synthesis, regulation of amino acids Ammonia synthesis and detoxification |
| − | * CARBOHYDRATE METABOLISM
| + | |
| | + | ===Carbohydrate Metabolism=== |
| | Blood glucose regulation Maintenance of glycogen reserve Regulation of intermediary carbohydrate metabolism | | Blood glucose regulation Maintenance of glycogen reserve Regulation of intermediary carbohydrate metabolism |
| − | * LIPID METABOLISM
| + | |
| | + | ===Lipid Metabolism=== |
| | Synthesis of cholesterol, phospholipids and lipoproteins; fatty acid oxidation Bile acid synthesis and regulation | | Synthesis of cholesterol, phospholipids and lipoproteins; fatty acid oxidation Bile acid synthesis and regulation |
| − | * BIOTRANSFORMATION AND EXCRETION
| + | |
| | + | ===Biotransformation and Excretion=== |
| | Bilirubin, ammonia, steroid hormones Drugs, copper, cholesterol | | Bilirubin, ammonia, steroid hormones Drugs, copper, cholesterol |
| − | * IMMUNOLOGICAL FUNCTIONS
| + | |
| | + | ===Immunological Functions=== |
| | Antigen trapping by Kupffer's cells Synthesis of complement, interleukin | | Antigen trapping by Kupffer's cells Synthesis of complement, interleukin |
| − | * VITAMIN ACTIVATION, STORAGE AND ELIMINATION
| + | |
| − | * STORAGE OF MINERALS (IRON, COPPER, ZINC, MANGANESE)
| + | ===Vitamin Storage, Activation and Elimination=== |
| − | * INACTIVATION OF ENDOCRINE HORMONE
| + | |
| | + | ===Storage of Minerals=== |
| | + | IRON, COPPER, ZINC, MANGANESe |
| | + | |
| | + | ===Inactivation of Endocrine Hormones=== |
| | | | |
| | ==Clinical Signs== | | ==Clinical Signs== |
| Line 67: |
Line 75: |
| | * Coagulation profile | | * Coagulation profile |
| | | | |
| | + | plasma ammonia |
| | + | abdominocentesis |
| | + | |
| | + | ===Biopsy=== |
| | + | |
| | + | ==Treatment== |
| | + | * Remove causative agent |
| | + | * Stop inflammation |
| | + | * Minimise fibrosis |
| | + | * Promote regeneration |
| | + | * Treat secondary complications such a ascites, secondary bacterial infection and hepatic encephalopathy. |
| | + | |
| | + | ==References== |
| | + | Rutgers, C (1996) '''Liver disease in dogs''' ''In Practice 1996 18: 433-44'' |
| | | | |
| | + | Rutgers, C (1996) ''Feline liver disease''' ''In Practice 1998 20: 16-2'' |
| | | | |
| | + | Dunn, j (1992) '''Assessment of liver damage and function''' ''In Practice 1992 14: 193-200'' |
| | | | |
| − | [[Category:Liver - General Pathology]]
| + | Bexfield, N & Watson, P (2006) '''Diagnosis of canine liver disease''' ''In Practice 2006 28: 444-45'' |
| − | [[Category:To_Do_-_Clinical]]
| |
| − | [[Category:To Do - Siobhan Brade]]
| |